Curis to Present at Upcoming Healthcare Conferences in September

Rhea-AI Summary

Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in two upcoming healthcare conferences in September 2024. James Dentzer, President and CEO, will represent Curis at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11): Company presentation on Sept. 11 at 1:00 pm ET.

2. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19): Fireside chat on Sept. 17 at 3:05 pm ET.

Webcasts for both presentations will be available on the Curis website in the 'Investors' section, providing investors with opportunities to gain insights into the company's progress and strategy.

News Market Reaction – CRIS

-1.14%

1 alert

-1.14% News Effect

On the day this news was published, CRIS declined 1.14%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LEXINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:

The H.C. Wainwright 26^th Annual Global Investment Conference being held September 9 – 11, 2024. Presentation details are as follows:

• Format: Company Presentation
• Date: Wednesday, September 11, 2024
• Time: 1:00 pm ET
• H.C. Wainwright webcast

The 2024 Cantor Fitzgerald Global Healthcare Conference being held September 17 – 19, 2024. Presentation details are as follows:

• Format: Fireside Chat
• Date: Tuesday, September 17, 2024
• Time: 3:05 pm ET
• Cantor webcast

Webcasts will be also available on the Curis website at www.curis.com in the 'Investors' section.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-302237422.html

SOURCE Curis, Inc.

FAQ

What conferences will Curis (CRIS) attend in September 2024?

Curis (CRIS) will attend two conferences in September 2024: the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, and the 2024 Cantor Fitzgerald Global Healthcare Conference from September 17-19.

When is Curis (CRIS) presenting at the H.C. Wainwright conference?

Curis (CRIS) will present at the H.C. Wainwright conference on Wednesday, September 11, 2024, at 1:00 pm ET.

What type of presentation will Curis (CRIS) give at the Cantor Fitzgerald conference?

Curis (CRIS) will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 17, 2024, at 3:05 pm ET.

Where can investors access the webcasts of Curis (CRIS) presentations?

Investors can access the webcasts of Curis (CRIS) presentations on the company's website at www.curis.com in the 'Investors' section.

What is the main product Curis (CRIS) is developing?

Curis (CRIS) is focused on developing emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.